دورية أكاديمية
GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer.
| العنوان: | GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. |
|---|---|
| المؤلفون: | Huntington, Kelsey E.1,2,3,4,5 (AUTHOR), Louie, Anna D.1,2,3,4,6,7 (AUTHOR), Srinivasan, Praveen R.1,2,3,4,6 (AUTHOR), Schorl, Christoph6,8,9 (AUTHOR), Lu, Shaolei1,3,4,6 (AUTHOR), Silverberg, David10 (AUTHOR), Newhouse, Daniel11 (AUTHOR), Wu, Zhijin12 (AUTHOR), Zhou, Lanlan1,2,3,4,6 (AUTHOR), Borden, Brittany A.6 (AUTHOR), Giles, Francis J.13 (AUTHOR), Dooner, Mark14 (AUTHOR), Carneiro, Benedito A.3,4,6,14 (AUTHOR), El-Deiry, Wafik S.1,2,3,4,5,6,14 (AUTHOR) wafik@brown.edu |
| المصدر: | International Journal of Molecular Sciences. Jul2023, Vol. 24 Issue 13, p10870. 33p. |
| مصطلحات موضوعية: | *TUMOR-infiltrating immune cells, *GRANZYMES, *PROGRAMMED cell death 1 receptors, *GLYCOGEN synthase kinase-3, *COLORECTAL cancer, *IMMUNE checkpoint proteins, *REGULATORY T cells, *IMMUNE response |
| مستخلص: | Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase that has been implicated in numerous oncogenic processes. GSK-3 inhibitor elraglusib (9-ING-41) has shown promising preclinical and clinical antitumor activity across multiple tumor types. Despite promising early-phase clinical trial results, there have been limited efforts to characterize the potential immunomodulatory properties of elraglusib. We report that elraglusib promotes immune cell-mediated tumor cell killing of microsatellite stable colorectal cancer (CRC) cells. Mechanistically, elraglusib sensitized CRC cells to immune-mediated cytotoxicity and enhanced immune cell effector function. Using western blots, we found that elraglusib decreased CRC cell expression of NF-κB p65 and several survival proteins. Using microarrays, we discovered that elraglusib upregulated the expression of proapoptotic and antiproliferative genes and downregulated the expression of cell proliferation, cell cycle progression, metastasis, TGFβ signaling, and anti-apoptotic genes in CRC cells. Elraglusib reduced CRC cell production of immunosuppressive molecules such as VEGF, GDF-15, and sPD-L1. Elraglusib increased immune cell IFN-γ secretion, which upregulated CRC cell gasdermin B expression to potentially enhance pyroptosis. Elraglusib enhanced immune effector function resulting in augmented granzyme B, IFN-γ, TNF-α, and TRAIL production. Using a syngeneic, immunocompetent murine model of microsatellite stable CRC, we evaluated elraglusib as a single agent or combined with immune checkpoint blockade (anti-PD-1/L1) and observed improved survival in the elraglusib and anti-PD-L1 group. Murine responders had increased tumor-infiltrating T cells, augmented granzyme B expression, and fewer regulatory T cells. Murine responders had reduced immunosuppressive (VEGF, VEGFR2) and elevated immunostimulatory (GM-CSF, IL-12p70) cytokine plasma concentrations. To determine the clinical significance, we then utilized elraglusib-treated patient plasma samples and found that reduced VEGF and BAFF and elevated IL-1 beta, CCL22, and CCL4 concentrations correlated with improved survival. Using paired tumor biopsies, we found that tumor-infiltrating immune cells had a reduced expression of inhibitory immune checkpoints (VISTA, PD-1, PD-L2) and an elevated expression of T-cell activation markers (CTLA-4, OX40L) after elraglusib treatment. These results address a significant gap in knowledge concerning the immunomodulatory mechanisms of GSK-3 inhibitor elraglusib, provide a rationale for the clinical evaluation of elraglusib in combination with immune checkpoint blockade, and are expected to have an impact on additional tumor types, besides CRC. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: | Academic Search Index |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
asx Academic Search Index 164919486 1377 6 Academic Journal academicJournal 1376.76416015625 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=164919486&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:asx&genre=article&issn=16616596&ISBN=&volume=24&issue=13&date=20230701&spage=10870&pages=10870-10902&title=International Journal of Molecular Sciences&atitle=GSK-3%20Inhibitor%20Elraglusib%20Enhances%20Tumor-Infiltrating%20Immune%20Cell%20Activation%20in%20Tumor%20Biopsies%20and%20Synergizes%20with%20Anti-PD-L1%20in%20a%20Murine%20Model%20of%20Colorectal%20Cancer.&id=DOI:10.3390/ijms241310870 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer.
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Huntington%2C+Kelsey+E%2E%22">Huntington, Kelsey E.</searchLink><relatesTo>1,2,3,4,5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Louie%2C+Anna+D%2E%22">Louie, Anna D.</searchLink><relatesTo>1,2,3,4,6,7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Srinivasan%2C+Praveen+R%2E%22">Srinivasan, Praveen R.</searchLink><relatesTo>1,2,3,4,6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Schorl%2C+Christoph%22">Schorl, Christoph</searchLink><relatesTo>6,8,9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lu%2C+Shaolei%22">Lu, Shaolei</searchLink><relatesTo>1,3,4,6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Silverberg%2C+David%22">Silverberg, David</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Newhouse%2C+Daniel%22">Newhouse, Daniel</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wu%2C+Zhijin%22">Wu, Zhijin</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zhou%2C+Lanlan%22">Zhou, Lanlan</searchLink><relatesTo>1,2,3,4,6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Borden%2C+Brittany+A%2E%22">Borden, Brittany A.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Giles%2C+Francis+J%2E%22">Giles, Francis J.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dooner%2C+Mark%22">Dooner, Mark</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Carneiro%2C+Benedito+A%2E%22">Carneiro, Benedito A.</searchLink><relatesTo>3,4,6,14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22El-Deiry%2C+Wafik+S%2E%22">El-Deiry, Wafik S.</searchLink><relatesTo>1,2,3,4,5,6,14</relatesTo> (AUTHOR)<i> wafik@brown.edu</i> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <searchLink fieldCode="JN" term="%22International+Journal+of+Molecular+Sciences%22">International Journal of Molecular Sciences</searchLink>. Jul2023, Vol. 24 Issue 13, p10870. 33p. ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => *<searchLink fieldCode="DE" term="%22TUMOR-infiltrating+immune+cells%22">TUMOR-infiltrating immune cells</searchLink><br />*<searchLink fieldCode="DE" term="%22GRANZYMES%22">GRANZYMES</searchLink><br />*<searchLink fieldCode="DE" term="%22PROGRAMMED+cell+death+1+receptors%22">PROGRAMMED cell death 1 receptors</searchLink><br />*<searchLink fieldCode="DE" term="%22GLYCOGEN+synthase+kinase-3%22">GLYCOGEN synthase kinase-3</searchLink><br />*<searchLink fieldCode="DE" term="%22COLORECTAL+cancer%22">COLORECTAL cancer</searchLink><br />*<searchLink fieldCode="DE" term="%22IMMUNE+checkpoint+proteins%22">IMMUNE checkpoint proteins</searchLink><br />*<searchLink fieldCode="DE" term="%22REGULATORY+T+cells%22">REGULATORY T cells</searchLink><br />*<searchLink fieldCode="DE" term="%22IMMUNE+response%22">IMMUNE response</searchLink> ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase that has been implicated in numerous oncogenic processes. GSK-3 inhibitor elraglusib (9-ING-41) has shown promising preclinical and clinical antitumor activity across multiple tumor types. Despite promising early-phase clinical trial results, there have been limited efforts to characterize the potential immunomodulatory properties of elraglusib. We report that elraglusib promotes immune cell-mediated tumor cell killing of microsatellite stable colorectal cancer (CRC) cells. Mechanistically, elraglusib sensitized CRC cells to immune-mediated cytotoxicity and enhanced immune cell effector function. Using western blots, we found that elraglusib decreased CRC cell expression of NF-κB p65 and several survival proteins. Using microarrays, we discovered that elraglusib upregulated the expression of proapoptotic and antiproliferative genes and downregulated the expression of cell proliferation, cell cycle progression, metastasis, TGFβ signaling, and anti-apoptotic genes in CRC cells. Elraglusib reduced CRC cell production of immunosuppressive molecules such as VEGF, GDF-15, and sPD-L1. Elraglusib increased immune cell IFN-γ secretion, which upregulated CRC cell gasdermin B expression to potentially enhance pyroptosis. Elraglusib enhanced immune effector function resulting in augmented granzyme B, IFN-γ, TNF-α, and TRAIL production. Using a syngeneic, immunocompetent murine model of microsatellite stable CRC, we evaluated elraglusib as a single agent or combined with immune checkpoint blockade (anti-PD-1/L1) and observed improved survival in the elraglusib and anti-PD-L1 group. Murine responders had increased tumor-infiltrating T cells, augmented granzyme B expression, and fewer regulatory T cells. Murine responders had reduced immunosuppressive (VEGF, VEGFR2) and elevated immunostimulatory (GM-CSF, IL-12p70) cytokine plasma concentrations. To determine the clinical significance, we then utilized elraglusib-treated patient plasma samples and found that reduced VEGF and BAFF and elevated IL-1 beta, CCL22, and CCL4 concentrations correlated with improved survival. Using paired tumor biopsies, we found that tumor-infiltrating immune cells had a reduced expression of inhibitory immune checkpoints (VISTA, PD-1, PD-L2) and an elevated expression of T-cell activation markers (CTLA-4, OX40L) after elraglusib treatment. These results address a significant gap in knowledge concerning the immunomodulatory mechanisms of GSK-3 inhibitor elraglusib, provide a rationale for the clinical evaluation of elraglusib in combination with immune checkpoint blockade, and are expected to have an impact on additional tumor types, besides CRC. [ABSTRACT FROM AUTHOR] ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.3390/ijms241310870
)
)
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 33
[StartPage] => 10870
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => TUMOR-infiltrating immune cells
[Type] => general
)
[1] => Array
(
[SubjectFull] => GRANZYMES
[Type] => general
)
[2] => Array
(
[SubjectFull] => PROGRAMMED cell death 1 receptors
[Type] => general
)
[3] => Array
(
[SubjectFull] => GLYCOGEN synthase kinase-3
[Type] => general
)
[4] => Array
(
[SubjectFull] => COLORECTAL cancer
[Type] => general
)
[5] => Array
(
[SubjectFull] => IMMUNE checkpoint proteins
[Type] => general
)
[6] => Array
(
[SubjectFull] => REGULATORY T cells
[Type] => general
)
[7] => Array
(
[SubjectFull] => IMMUNE response
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer.
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Huntington, Kelsey E.
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Louie, Anna D.
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Srinivasan, Praveen R.
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Schorl, Christoph
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lu, Shaolei
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Silverberg, David
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Newhouse, Daniel
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Wu, Zhijin
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Zhou, Lanlan
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Borden, Brittany A.
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Giles, Francis J.
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Dooner, Mark
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Carneiro, Benedito A.
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => El-Deiry, Wafik S.
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 07
[Text] => Jul2023
[Type] => published
[Y] => 2023
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 16616596
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 24
)
[1] => Array
(
[Type] => issue
[Value] => 13
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => International Journal of Molecular Sciences
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |